Skip to content

Liquidia

US · LQDA #2623 by market cap Listed 2018
26.68 +0.77 +2.97%
Live - 5344 symbols - heartbeat 126s ago · 2026-10-08 08:27
Pre-market 26.80 +0.45%
After-hours 26.40 -1.05%
Overnight 26.60 -0.30%
Market cap
2.39B
P/B
12.24
EPS
-0.80
Reader sentiment Are you bullish or bearish on LQDA?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 11.89 In line with history 55th percentile
5-year average 29.84 · #64 of 70 in Drug Manufacturers - Specialty & Generic
P/E ratio 18.51 Expensive vs history 92nd percentile
5-year average 12.76 · forward 12.65 · #13 of 25 in Drug Manufacturers - Specialty & Generic
P/S ratio 5.14 Cheap vs history 0th percentile
5-year average 45.00 · forward 3.74 · #60 of 80 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Liquidia (LQDA) 2.39B 19.06 12.24 0.00%
Takeda Pharmaceutical (TAK) 58.68B -55.67 1.23 3.26%
Teva Pharmaceutical Industries (TEVA) 45.70B 65.30 5.89 0.00%
Haleon (HLN) 39.67B 18.87 1.83 2.11%
Zoetis (ZTS) 29.57B 11.67 9.39 2.88%
United Therapeutics (UTHR) 23.38B 19.53 3.65 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value21.17 Economic moatNarrow UncertaintyVery High

Trading 20.7% above Morningstar's fair value estimate.

Fair value

Liquidia Corp earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 31% premium over our quantitative fair value estimate of $21.17 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The firm's valuation metrics undermine our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 7.6% lies in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

On a different note, the firm's solid growth is reassuring. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. The firm's revenue 5-year growth, for example, sits in the top 1% globally. Relatively strong trailing five-year revenue growth suggests a compelling trajectory for future sales and earnings, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-10-08 08:27:01 · For reference only, not investment advice and not tailored to your situation.